Dabrafenib in combination with trametinib is currently in clinical development for the treatment
of paediatric BRAF V600 mutant relapsed or refractory high-grade glioma (HGG), or BRAF V600
mutant low grade glioma (LGG) with progressive disease. Brain tumours in children arise from
different types of cells in the brain. Gliomas are the most common type of central nervous system
tumours. Symptoms of glioma are non-specific and include headache, nausea and vomiting.
Current treatment options are very limited and include surgery, radiotherapy and chemotherapy
for which the best drugs are still under investigation.
Dabrafenib with trametinib for treating paediatric BRAF V600 mutated high-grade or low-grade glioma
Dabrafenib in combination with trametinib is currently in clinical development for the treatment of paediatric BRAF V600 mutant relapsed or refractory high-grade glioma (HGG), or BRAF V600 mutant low grade glioma (LGG) with progressive disease. Brain tumours in children arise from different types of cells in the brain.
Interventions:
Dabrafenib (Tafinlar; GSK2118436; dabrafenib mesilate)
, Trametinib (Mekinist; TMT212; GSK-1120212B; GSK1120212; JTP-74057; trametinib dimethyl sulfoxide)
Indications:
Glioma
Therapeutic Areas:
Neurological Cancer
Year:
2022